# EDGAR Filing Document

**Accession Number:** 0001412558
**File Stem:** 0001654954-23-003687
**Filing Date:** 2023-3
**Character Count:** 4349
**Document Hash:** 3f09313743f83de8eff5a93270deefa1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-003687.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001654954-23-003687

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 7

**CONFORMED PERIOD OF REPORT**: 20230328

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evotec SE
- **CENTRAL INDEX KEY:** 0001412558
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34041
- **FILM NUMBER:** 23766762

**BUSINESS ADDRESS:**
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **STATE:** 2M
- **ZIP:** 22419
- **BUSINESS PHONE:** 49-40-560-810

**MAIL ADDRESS:**
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **STATE:** 2M
- **ZIP:** 22419

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Evotec AG
- **DATE OF NAME CHANGE:** 20070917

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE MONTH OF MARCH 2023** 

**COMMISSION FILE NUMBER 001-34041**

---

| |
|:---|
| **Evotec SE** |
| (Translation of registrant's name into English) |

---

**Essener Bogen 7**

**22419 Hamburg**

**Germany**

**Tel: +49 40 560810** 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On March 28, 2023, Evotec SE (the "Company") announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb (NYSE:BMY), originally signed in 2016. The ad hoc release is attached hereto as Exhibit 99.1. An accompanying press release is attached hereto as Exhibit 99.2.

2<br>

**SIGNATURE**

Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Evotec SE** | **Evotec SE** |
|  | By: | /s/ Enno Spillner |
|  |  | Name: Enno Spillner |
|  |  | Title: Chief Financial Officer |
| Date: March 28, 2023 |  |  |

---

3<br>

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| <u>Exhibit</u> | <u>Description of Exhibit</u> |
| [99.1](evo_ex991.htm) | [Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership](evo_ex991.htm) |
| [99.2](evo_ex992.htm) | [Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership](evo_ex992.htm) |

---

4<br>

## Exhibit 99.1

**EXHIBIT 99.1**

![](evo_ex991img1.jpg)

28 March 2023

**Ad hoc release according to Article 17 MAR of the Regulation (EU) No 596/2014**

**Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership** 

**Hamburg, Germany** – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its strategic partnership with Bristol Myers Squibb (NYSE:BMY) in neurodegeneration, originally signed in 2016. Aim of the 8-year extension of the strategic alliance is to further broaden the programme pipeline in neurodegenerative diseases.

Evotec receives a $50 m upfront payment, undisclosed license and performance milestone payments, as well as tiered royalties up to low double-digit percentages on product sales. Including the upfront and downstream performance milestone payments, the overall transaction results in a deal potential of $4 bn.

– End of ad hoc release –

**Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, werner.lanthaler@evotec.com**

## Exhibit 99.2

&nbsp;&nbsp;&nbsp;&nbsp;**EXHIBIT 99.2**

![](evo_ex992img1.jpg)

![](evo_ex992img2.jpg)

![](evo_ex992img3.jpg)